title: High dose of Lamivudine and resistance in patients with chronic hepatitis B.
abstract: Background. Lamivudine is the most affordable drug used for chronic hepatitis B and has a high safety profile. With the daily dose of 100 mg there is progressive appearance of resistance to lamivudine therapy. In our study we used 150 mg of lamivudine daily as a standard dose which warrants further exploration for the efficacy of the drug. Aims of the Study. To assess the efficacy of lamivudine 150 mg daily on resistance in patients with chronic hepatitis B. Methods. This retrospective study consists of 53 patients with chronic hepatitis B treated with 150 mg of lamivudine daily. The biochemical and virological response to the treatment were recorded at a 1-year and 2-, 3-, 4-, and 5-year period and time of emergence of resistance to the treatment was noted. Results. The mean age of the patients was 54 years with 80% being males. The resistance to lamivudine 150 mg daily at 1 year and 2, 3, and 5 years was 12.5%, 22.5%, 37.5%, and 60%, respectively, which is much less compared to the standard dose of 100 mg of lamivudine. Conclusions. Lamivudine is safe and a higher dose of 150 mg daily delays the resistance in patients with chronic hepatitis B.
authors.affiliation: Department of Medicine, Division of Gastroenterology, Hamad Medical Corporation (HMC), 2 South 2, P.O. Box 3050, Doha, Qatar.
authors.forename: Hamid Ullah
authors.initials: HU
authors.lastname: Wani
authors.affiliation: Department of Medicine, Division of Gastroenterology, Hamad Medical Corporation (HMC), 2 South 2, P.O. Box 3050, Doha, Qatar.
authors.forename: Saad
authors.initials: S
authors.lastname: Al Kaabi
authors.affiliation: Department of Medicine, Division of Gastroenterology, Hamad Medical Corporation (HMC), 2 South 2, P.O. Box 3050, Doha, Qatar.
authors.forename: Manik
authors.identifier: 0000-0002-8838-1738
authors.initials: M
authors.lastname: Sharma
authors.affiliation: Department of Medicine, Division of Gastroenterology, Hamad Medical Corporation (HMC), 2 South 2, P.O. Box 3050, Doha, Qatar.
authors.forename: Rajvir
authors.initials: R
authors.lastname: Singh
authors.affiliation: Department of Medicine, Division of Gastroenterology, Hamad Medical Corporation (HMC), 2 South 2, P.O. Box 3050, Doha, Qatar.
authors.forename: Anil
authors.initials: A
authors.lastname: John
authors.affiliation: Department of Medicine, Division of Gastroenterology, Hamad Medical Corporation (HMC), 2 South 2, P.O. Box 3050, Doha, Qatar.
authors.forename: Moutaz
authors.initials: M
authors.lastname: Derbala
authors.affiliation: Department of Medicine, Division of Gastroenterology, Hamad Medical Corporation (HMC), 2 South 2, P.O. Box 3050, Doha, Qatar.
authors.forename: Muneera J
authors.initials: MJ
authors.lastname: Al-Mohannadi